Respiratory Diseases Drugs Global Market Forecast To 2022

North America was the largest region in the global respiratory diseases drugs market, accounting for 42% of the market in 2018. Western Europe was the second largest region accounting for 27% of the global respiratory diseases drugs market. Africa was the smallest region in the global respiratory diseases drugs market.

The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.

Tags: Global Respiratory Diseases Drugs Market, Global Respiratory Diseases Drugs Market Forecast, Global Respiratory Diseases Drugs Market Research Report, Global Respiratory Diseases Drugs Market Trends